The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Janssen; Takeda
Speakers' Bureau - Abbvie; Janssen
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
 
John Kuruvilla
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen; Karyopharm Therapeutics; Merck; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Gilead Sciences; Karyopharm Therapeutics; Merck; Roche; Seagen
Research Funding - Celgene; Janssen; Roche
 
Radhakrishnan Ramchandren
Consulting or Advisory Role - Bristol-Myers Squibb; Pharmacyclics/Janssen; Sandoz-Novartis; Seagen
Research Funding - Genentech (Inst); Janssen (Inst); Merck (Inst); Seagen (Inst)
 
Armando Santoro
Consulting or Advisory Role - ARQULE; Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Ewa Paszkiewicz-Kozik
Travel, Accommodations, Expenses - Celgene; Roche; Takeda
 
Robin Gasiorowski
Honoraria - Abbvie; MSD; Novartis; Takeda
 
Nathalie Johnson
Honoraria - Merck; Roche/Genentech
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Abbvie
 
Vladimir Melnichenko
No Relationships to Disclose
 
Laura Maria Fogliatto
No Relationships to Disclose
 
Iara Goncalves
Consulting or Advisory Role - Janssen
Speakers' Bureau - Janssen
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen; Merck; Novartis; Takeda
 
Jose de Oliveira
No Relationships to Disclose
 
Valeria Buccheri
Consulting or Advisory Role - AstraZeneca; AstraZeneca
Research Funding - Merck Sharp & Dohme (Inst); MSD (Inst); Roche (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Takeda (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Abbvie; Takeda; Takeda
 
Guilherme Fleury Perini
No Relationships to Disclose
 
Neta Goldschmidt
No Relationships to Disclose
 
Sergey Alekseev
No Relationships to Disclose
 
Iryna Kryachok
Consulting or Advisory Role - Janssen; Takeda
Research Funding - Abbvie; Acerta Pharma; Bayer; Debiopharm Group; Janssen; Karyopharm Therapeutics; MSD
Expert Testimony - Janssen; Takeda
Travel, Accommodations, Expenses - Abbvie; MSD; Roche; Takeda
 
Naohiro Sekiguchi
Research Funding - A2 Healthcare (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); PPD-SNBL (Inst); Sumitomo Group (Inst)
 
Ying Zhu
Employment - Merck
 
Akash Nahar
Employment - Merck
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Pier Luigi Zinzani
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kiowa Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; Sanofi; SERVIER; Verastem
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kiowa Kirin; MSD; Portola Pharmaceuticals; Roche; SERVIER; Verastem